For instance, the first US Food and Drug Administration-approved cancer vaccine Sipuleucel-T was developed from autologous DCs loaded with the engineered fusion protein of prostatic acid phosphatase and GM-CSF; this vaccine showed encouraging results in prolonging median survival in patients with castration-resistant prostate cancer 32. Here, CSF2 is linked to prostate carcinoma.